Navigation Links
Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Date:11/7/2011

or 28 weeks; or
  • BI 201335 120 mg QD plus BI 207127 600 mg TID without RBV for 28 weeks.

  • Other BI data being presented at the meeting include:

    • SILEN-C3: Treatment for 12 or 24 Weeks with BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin (P/R) in Treatment-Naive Patients with Chronic Genotype-1 HCV Infection (Abstract 36. D. Dieterich, et al. November 6, 4:15 p.m. - 4:30 p.m. PT)
    • Characterization of HCV NS3 Variants that Emerged During Virologic Breakthrough and Relapse from BI 201335 Phase 2 SILEN-C1 Study (Poster 1339. G. Kukolj, et al. November 7, 8:00 a.m. - 5:00 p.m. PT)
    • Treatment with the Second Generation HCV Protease Inhibitor BI 201335 Results in High and Consistent SVR Rates – Results from SILEN-C1 in Treatment-Naive Patients Across Different Baseline Factors (Abstract 226. M.S. Sulkowski, et al. November 8, 8:45 a.m. - 9:00 a.m. PT)
    • High Sustained Virologic Response Following Interferon-Free Treatment of Chronic HCV GT1 Infection for Four Weeks with HCV Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127 and Ribavirin, Followed by BI 201335 and PegIFN/Ribavirin – the SOUND-C1 Study (Abstract 249. S. Zeuzem, et al. November 8, 11:15 a.m. - 11:30 a.m. PT)

    About Hepatitis C Virus

    HCV is an infectious disease of the liver and is a leading cause of chronic liver disease, transplant and failure that affects as many as 175 million people globally, with three to four million new infections occurring each year. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. Chronic HCV infection is the cause of an estimated 8,000 to 10,000 deaths annually in the United States. The majority – about 75 to 85 percent – of HCV cases will develop into chronic infection. It is estimated 20 percent of patients with ch
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    2. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
    3. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
    4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    5. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
    6. Hepatitis C Phase 2A Trial Positive Results
    7. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
    8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
    9. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
    10. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
    11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
    (Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
    (Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
    Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
    ... 6 month results from long term durability study presented ... Section meeting of the American Urological Association, ... of innovative therapies in women,s health, announced today that,six ... to,evaluate the long term durability of the Renessa(R) treatment ...
    ... Community Oncology,Alliance (COA), representing community cancer centers ... & Medicaid Services (CMS),reconsider its decision to ... to,vital anemia-fighting drugs. Effective July 30, 2007, ... oncologists, use of,anemia-fighting drugs, referred to as ...
    Cached Medicine Technology:New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 2New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 3Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 2
    (Date:10/31/2014)... 2014 (HealthDay News) -- Carving pumpkins and trick-or-treating may ... children to emergency rooms in the United States every ... had the fifth highest number of ER visits involving ... data from the National Electronic Injury Surveillance System. ... head, noted the American Academy of Orthopaedic Surgeons and ...
    (Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... all public health tactics known to prevent Ebola transmission ... epidemic, a new study reports. Four practices in ... way, immediately isolating new patients, tracing people potentially exposed ... care workers -- can stop the epidemic within six ...
    (Date:10/31/2014)... National Institutes of Health will facilitate communication among ... health research, from diagnosis to treatment. The Research ... the National Institute of Mental Health (NIMH), part ... institute,s RDoC initiative. , The aim of ... of research that translates basic science into clinical ...
    (Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
    (Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
    Breaking Medicine News(10 mins):Health News:Halloween at the ER Is No Treat 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 3Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3
    ... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
    ... Professor of Public Health and Director of Health Promotion ... evidence that supports relationships seen in adolescents between insulin ... fat and identifies additional potential early markers of insulin ... including fat in muscle cells, blood pressure, physical activity, ...
    ... HealthDay Reporter , FRIDAY, July 9 (HealthDay News) -- One ... of Avandia, new doubts surfaced Friday on a key trial ... A medical reviewer for the U.S. Food and Drug ... that drugmaker GlaxoSmithKline,s "mishandling" of trial results may have ...
    ... the 52nd meeting of the American Association of Physicists ... 22, 2010 in Philadelphia, PA, thousands of scientists and ... developments in medical imaging and radiation therapy, examine new ... ethical and regulatory issues that face the field today. ...
    ... Researchers at Brown University have found that the length of ... doubled during the last 10 years. The study, which will ... the American Geriatrics Society , evaluated hospice use in U.S. ... treatment time has increased from 46 to 93 days. The ...
    ... HCG True Diet offers ... ... photos and revamped the before and after section of the website. The pictures can be ... taken of a patient before they start the HCG True Diet and after they finish the ...
    Cached Medicine News:Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 2Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 2Health News:FDA Reviewer Questions Results of Key Avandia Trial 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 2Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 3Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 5Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 6Health News:Study: Medicare policy may account for growing length of hospice stays in nursing homes 2Health News:See New HCG Diet Before and After Photos 2
    MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
    VACUETTE PaediatricMulti-Sample Needle...
    ... Blood Collection Needles are preominantly used for ... single-use. The colour of the needle protective ... needle gauges. For example, yellow symbolises the ... 21 G (0.80 mm) and black 22 ...
    This is adapted to microplate or card....
    Medicine Products: